Komori
Financial results presentation206APRISM BioLab Co.,LTDPharmaceuticals

Notice of On-Demand Availability of the Presentation Video from the First-Half Results Briefing for the Fiscal Year Ending September 2026

The presentation video used at the briefing on financial results for the interim period of the fiscal year ending September 2026 has been made available on demand, including the question-and-answer session. It will be available for six months from the publication date.

Worth reading
7Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Contents of this document

Financial results presentationInterim period of the fiscal year ending September 2026

No explanation of the document’s contents could be extracted from this disclosure. Videos and transcripts of earnings presentations, as well as notices of presentation dates, may be documents announcing that the material has been published and may not contain the underlying figures or explanations.

Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period CoveredInterim period of the fiscal year ending September 2026
Items this document does not state (29)
Net SalesOperating profitOrdinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To promote dialogue with shareholders and investors and create opportunities to deepen their understanding of the company through the dissemination of information.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of On-Demand Availability of the Presentation Video from the First-Half Results Briefing for the Fiscal Year Ending September 2026 | PRISM BioLab Co.,LTD (206A) timely disclosure | Komori